Mayflower Financial Advisors LLC Purchases 2,380 Shares of Novo Nordisk A/S $NVO

Mayflower Financial Advisors LLC lifted its position in Novo Nordisk A/S (NYSE:NVO) by 46.9% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 7,454 shares of the company’s stock after buying an additional 2,380 shares during the quarter. Mayflower Financial Advisors LLC’s holdings in Novo Nordisk A/S were worth $514,000 as of its most recent filing with the SEC.

Other large investors have also recently added to or reduced their stakes in the company. Unified Investment Management bought a new stake in shares of Novo Nordisk A/S in the second quarter valued at approximately $692,000. Acadian Asset Management LLC boosted its position in shares of Novo Nordisk A/S by 15,919.9% in the first quarter. Acadian Asset Management LLC now owns 1,044,658 shares of the company’s stock valued at $72,523,000 after acquiring an additional 1,038,137 shares during the period. Guild Investment Management Inc. boosted its position in shares of Novo Nordisk A/S by 20.7% in the second quarter. Guild Investment Management Inc. now owns 36,995 shares of the company’s stock valued at $2,553,000 after acquiring an additional 6,345 shares during the period. Norden Group LLC boosted its position in shares of Novo Nordisk A/S by 216.3% in the second quarter. Norden Group LLC now owns 96,332 shares of the company’s stock valued at $6,649,000 after acquiring an additional 65,877 shares during the period. Finally, Farther Finance Advisors LLC boosted its position in shares of Novo Nordisk A/S by 48.7% in the second quarter. Farther Finance Advisors LLC now owns 103,138 shares of the company’s stock valued at $7,119,000 after acquiring an additional 33,794 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO opened at $51.36 on Thursday. The business has a fifty day simple moving average of $56.43 and a 200 day simple moving average of $62.14. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $229.30 billion, a price-to-earnings ratio of 14.11, a PEG ratio of 2.37 and a beta of 0.68. Novo Nordisk A/S has a one year low of $45.05 and a one year high of $113.76.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The business had revenue of $11.69 billion during the quarter, compared to analyst estimates of $77.51 billion. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were paid a dividend of $0.4119 per share. This represents a yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S’s dividend payout ratio is currently 22.53%.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on NVO shares. Berenberg Bank raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Wednesday, September 17th. Morgan Stanley cut Novo Nordisk A/S from an “overweight” rating to an “underweight” rating and reduced their price objective for the company from $59.00 to $47.00 in a research report on Monday, September 29th. Rothschild Redb raised Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 16th. BMO Capital Markets restated a “market perform” rating and issued a $55.00 target price (up from $50.00) on shares of Novo Nordisk A/S in a research note on Tuesday, October 14th. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, September 9th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $76.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.